GC Biopharma Corp - Company Profile
Powered by 
All the data and insights you need on GC Biopharma Corp in one report.
$295
- Save hours of research time and resources with
our up-to-date GC Biopharma Corp Strategy Report
- Understand GC Biopharma Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
GC Biopharma Corp (GC Biopharma), formerly known as GC Pharma, a subsidiary of Green Cross Holdings Corp, provides plasma protein therapeutics and vaccines. The company develops, manufactures, and markets a wide product portfolio comprising plasma derivatives including albumin, immunoglobulin, and antithrombin; vaccines for infectious diseases; prescription drugs for treating cardiovascular, respiratory, central nervous system (CNS), gastrointestinal and immunology diseases, musculoskeletal disorders, genetic disorders, metabolic disorders and hematological disorders; and Over-the-counter (OTC) drugs including anti-inflammatory drugs, anti-allergic products, and others. The company focuses its research and development activities on developing drugs for treatment of cancer, tuberculosis, and hunter syndrome, among others. GC Biopharma is headquartered Yongin, Gyeonggi-do, South Korea.
Headquarters
South Korea
Address
107, Ihyeon-Ro 30beon-Gil, Giheung-Gu, Yongin, 16924
Website
gcbiopharma.com
Telephone
82 31 2609300
No of Employees
1,766
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
006280 (KRX)
Revenue (2022)
$1.2B
-4.9%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-140.7%
(2022 vs 2021)
Market Cap*
$931.7M
Net Profit Margin (2022)
XYZ
-142.9%
(2022 vs 2021)
* As of and is in US$
GC Biopharma Corp premium industry data and analytics
Products and Services
| Products |
|---|
| - |
| Prescription Drugs |
| Over-The-Counter Drugs |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | New Products/Services | In January, the company introduced a 30-tablet version of its anti-inflammatory drug, the Tak-Sen soft cap. |
| 2023 | Regulatory Approval | In December, the company secured approval from The Food and Drug Administration for Alyglo 10% liquid to treat primary humoral immunodeficiency in adults. |
| 2023 | Contracts/Agreements | In October, the company and Immetas Therapeutics entered into a research collaboration to discover and develop novel mRNA therapeutics for the treatment of a broad range of autoimmune diseases. |
Competitor Comparison
| Key Parameters | GC Biopharma Corp | Yuhan Corp | Huons Global Co Ltd | Jeil Pharmaceutical Co Ltd | Suheung Capsule Co Ltd |
|---|---|---|---|---|---|
| Headquarters | South Korea | South Korea | South Korea | South Korea | South Korea |
| City | Yongin | Seoul | Seongnam | Seoul | Cheongju |
| No. of Employees | 1,766 | 1,594 | 541 | 978 | 727 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Il-sup Huh | Chairman | Executive Board | 2009 | - |
| Eun-chul Huh | Chief Executive Officer; President | Senior Management | 2015 | - |
| Seung-Ho Lim | Director; Head-Production | Executive Board | 2022 | - |
| Namkoong Hyun | Director; Head- Domestic Sales | Executive Board | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward